Three independent discounted-cash-flow-style models value Ionis Pharmaceuticals, Inc. every trading day. 0 of 3 currently price IONS above its market price.
| Free Cash Flow model | $-192.93 |
| Excess Profit model | $-178.04 |
| Residual Earnings model | $-0.15 |
| Dividend Discount model | — |
| Piotroski F-Score | 2 / 9 |
| Return on invested capital | -14.9% |
| Net debt / EBITDA | — |
| Gross margin | +98.3% |
| Revenue CAGR | +17.1% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -3.4% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open IONS in StockKitty